Investment Trends for the IO 2.0 Wave

Jonathan Fassberg comes to Oppenheimer with 30 years of relevant experience, having worked at DuPont Pharmaceuticals as well as several boutique investment banks as an equity research analyst early in his career.

Asthika Goonewardene, MBA, is a Managing Director at Truist Securities covering biotechnology companies with a focus on cell therapy, immuno-oncology, and antibody technology. Prior to joining the STRH Biotech team in 2019, Mr Goonewardene was a senior analyst with Bloomberg Intelligence, leading coverage of the global biotech sector. Before joining Bloomberg in 2011, Mr Goonewardene worked as a senior management consultant at Datamonitor.  He started his career as an analyst at OSI Pharmaceuticals in 2005, and first joined the sell-side in 2007, with the biotech team at Piper Jaffray in London. Mr Goonewardene holds a BS in Biotechnology and an MBA in Technology Management from Rochester Institute of Technology.

Irina Margine, PhD, is a private equity principal on the Wellington Private Equity Team, where she focuses on private company investing in the area of Biotechnology. Prior to joining Wellington Management in 2019, Dr Margine was on the Equity Research Team at Cowen and Co., covering small and mid-cap biotechnology companies. Previously, she worked in risk management within JPMorgan’s wholesale lending businesses. Dr Margine earned her PhD in microbiology from the Icahn School of Medicine at Mount Sinai in New York and her master of science in biomolecular sciences from Utrecht University in the Netherlands.